203065-56-9

Basic information

• Product Name: Benzoic acid, 2-(acetyloxy)-, 4-formylphenyl ester
• CAS NO: 203065-56-9
• Molecular Formula: C16H12O5
• Molecular Weight: 284.268
• Mol File: 203065-56-9.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 2-(acetyloxy)-, 4-formylphenyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 2-(acetyloxy)-, 4-formylphenyl ester(203065-56-9)
• EPA Substance Registry System: Benzoic acid, 2-(acetyloxy)-, 4-formylphenyl ester(203065-56-9)

Safety Data

• Hazardous Substances Data: 203065-56-9(Hazardous Substances Data)

Upstream product

• 123-08-0 4-hydroxy-benzaldehyde 
• 5538-51-2 O-acetylsalicyloyl chloride 
• 50-78-2 aspirin 
• 7757-82-6 sodium sulfate 

Downstream Products

• 287118-97-2 [2-(acetyloxy)benzoicacid 4-(nitrooxy methyl)phenyl ester] 
• 410071-22-6 2-(acetyloxy)benzoic acid 4-(chloromethyl) phenyl ester 
• 905584-36-3 2-acetoxy-benzoic acid 4-[bis-(4-hydroxy-2-oxo-2H-chromen-3-yl)-methyl]-phenyl ester 
• 123-08-0 4-hydroxy-benzaldehyde 
• 50-78-2 aspirin 

Relevant articles and documents

Fluorescent probe for detecting activity of hydrogen peroxide, preparation and application

The invention provides a fluorescent probe for detecting the activity of hydrogen peroxide. The fluorescent probe is obtained by the following steps: dissolving aspirin in dichloromethane, adding 1-hydroxybenzotriazole, 1-ethyl-(3-dimethylaminopropyl) car

Chemical insights in the concept of hybrid drugs: The antitumor effect of nitric oxide-donating aspirin involves a quinone methide but not nitric oxide nor aspirin

Hybrid drug 1 (NO-ASA) continues to attract intense research from chemists and biologists alike. It consists of ASA and a -ONO2 group connected through a spacer and is in preclinical development as an antitumor drug. We report that, contrary to current beliefs, neither ASA nor NO contributes to this antitumor effect. Rather, an unsubstituted QM was identified as the sole cytotoxic agent. QM forms from 1 after carboxylic ester hydrolysis and, in accordance with the HSAB theory, selectively reacts with cellular GSH, which in turn triggers cell death. Remarkably, a derivative lacking ASA and the -ONO 2 group is 10 times more effective than 1. Thus, our data provide a conclusive molecular mechanism for the antitumor activity of 1. Equally importantly, we show for the first time that a "presumed invisible" linker in a hybrid drug is not so invisible after all and is in fact solely responsible for the biological effect.

Drugs for diabetes

Use for the diabetes treatment of compounds or salts thereof, having the following general formula (I): A-(B)b0—(C)c0—NO2 wherein A contains the radical of a drug having an antiiflammatory or analgesic activity, B is a bivalen: linking group wherein the precursor must meet the tests described in the application, C is a a bivalent linking group as defined in the invention.